Attenuated Novel SARS Coronavirus 2 Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient on Ruxolitinib

Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Foss, Francine M., Rubinowitz, Ami, Landry, Marie L., Isufi, Iris, Gowda, Lohith, Seropian, Stuart, Perreault, Sarah, Shenoi, Sheela V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316063/
https://www.ncbi.nlm.nih.gov/pubmed/32727701
http://dx.doi.org/10.1016/j.clml.2020.06.014
Descripción
Sumario:Severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) has a high death rate in patients with comorbidities or in an immunocompromised state. We report a mild and attenuated SARS CoV-2 infection in a patient who is 17 months post stem cell transplantation and maintained on the JAK/STAT inhibitor ruxolitinib, a proposed novel therapy for SARS CoV-2 pneumonia.

Ejemplares similares